VA Prostate Cancer Residuals Rating Evidence Checklist

A VA prostate cancer residuals rating is not built from the cancer diagnosis alone after active treatment ends. The file should show the treatment timeline, whether cancer is still active or has recurred, when the six-month review applies, and which residual lane is predominant: voiding dysfunction, renal dysfunction, urinary tract infection, erectile dysfunction, scars, or other documented functional loss.

This guide is for veterans with service-connected prostate cancer, post-surgery residuals, radiation or hormone-treatment residuals, urinary leakage, nighttime voiding, pad changes, ED, surgical scars, recurrence concerns, or a proposed reduction after cancer treatment. TYFYS is a private paid service. We are not the VA, not a VSO, and not a law firm. This is educational evidence strategy, not legal or medical advice.

Table of Contents

• Why prostate cancer residuals get underrated
• How VA rates prostate cancer and residuals
• The 10-part evidence checklist
• What the DBQs should document
• Service-connection and exposure evidence
• Common mistakes that weaken residual ratings
• How to organize the file
• How TYFYS fits into the process
• FAQ

Why prostate cancer residuals get underrated

Prostate cancer files can look strong at first because the diagnosis and treatment are serious. The problem usually appears later, when VA moves from the active cancer rating to residuals. If the file only says "status post prostate cancer" without urinary details, ED details, scar details, renal facts, or recurrence status, the post-treatment rating can miss the actual disability picture.

The evidence should make the current stage easy to see. Active cancer, recent treatment, remission, biochemical recurrence concerns, surgical residuals, radiation residuals, and long-term urinary leakage are not the same file. A reviewer should not have to infer whether the issue is still active malignancy, post-treatment voiding dysfunction, renal dysfunction, ED/SMC-K, or a separate surgical scar.

How VA rates prostate cancer and residuals

VA rates malignant neoplasms of the genitourinary system under 38 C.F.R. section 4.115b. Diagnostic Code 7528 lists malignant genitourinary neoplasms at 100%. The note explains that after surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure ends, the 100% rating continues until a mandatory VA examination at the expiration of six months.

The same note says that if there has been no local recurrence or metastasis, VA rates the condition on residuals as voiding dysfunction or renal dysfunction, whichever is predominant. That is why the evidence packet should preserve both cancer-treatment records and the residual evidence that follows treatment.

File stage	What the record should show	Evidence examples
Active cancer or active treatment	Diagnosis, treatment type, start and end dates, and whether disease is active.	Pathology report, oncology notes, surgery report, radiation record, chemotherapy or hormone-therapy notes, imaging.
Six-month review	When treatment ended and what exam or medical evidence shows at review.	VA exam notice, DBQ, oncology follow-up, PSA trend, recurrence or metastasis assessment.
Voiding dysfunction	Leakage, absorbent material changes, appliance use, urinary frequency, nighttime wake-ups, or obstruction.	Bladder log, pad-change log, urology note, catheter or appliance record, Urinary Tract DBQ.
Renal dysfunction	Whether kidney function is the predominant residual lane.	eGFR/GFR, creatinine, ACR, nephrology interpretation, Kidney DBQ facts.
Separate residual facts	ED, SMC-K facts, scars, pain, fatigue, treatment side effects, or functional limits.	Male Reproductive Organ DBQ, ED records, scar measurements, personal statement, work-impact facts.

For urinary residuals, 38 C.F.R. section 4.115a separates urine leakage, urinary frequency, and obstructed voiding. Leakage can depend on appliance use or how often absorbent materials must be changed. Frequency depends on daytime voiding intervals and nighttime awakenings. Obstruction depends on facts like catheterization, retention, stricture disease, and objective urology findings.

The 10-part evidence checklist

Use this checklist before a prostate cancer residuals claim, increase, supplemental claim, C&P exam, or proposed-reduction response. Many weak files are missing one of these proof categories.

1. Diagnosis and pathology record

Keep the pathology report, biopsy report, operative report, imaging, oncology diagnosis, and any record that identifies prostate cancer clearly. If the diagnosis date differs from the treatment start date, make both dates visible.

2. Treatment timeline

Create a date map for surgery, radiation, antineoplastic chemotherapy, hormone therapy, active surveillance, or other treatment. Do not guess whether a treatment counts for rating purposes. Preserve the clinician's notes and let the record explain what happened and when.

3. Six-month review date

Identify when the relevant therapeutic procedure ended and when the six-month review should occur. If VA proposes to reduce the rating, compare the proposed action to the treatment end date, the exam date, and the current residual evidence.

4. Recurrence, metastasis, and PSA trend proof

Organize PSA results, oncology follow-ups, imaging, recurrence discussions, metastasis workups, and treatment-restart notes. The file should not leave recurrence status unclear. If the veteran is worried about biochemical recurrence, the medical record should explain the concern rather than relying on a lay interpretation of lab numbers.

5. Voiding dysfunction and leakage evidence

If leakage is the main residual, document whether absorbent materials are required and how many times they must be changed per day. Keep supply records, prescriptions, urology notes, and a pad-change log. The difference between less than 2 changes, 2 to 4 changes, and more than 4 changes per day can matter.

6. Urinary frequency and nighttime wake-ups

Track daytime voiding intervals and nighttime awakenings to void. A simple 7-day bladder log can make the pattern clearer than a statement that says "I go constantly." Include sleep disruption and work impact, but keep the rating numbers clean.

7. Obstruction, catheter, appliance, or infection records

Preserve urology testing, post-void residuals, uroflowmetry, stricture treatment, catheter instructions, appliance records, recurrent urinary tract infection notes, and hospitalizations if they apply. Obstructed voiding and infection evidence should not be buried under a generic incontinence paragraph.

8. Renal dysfunction evidence

If kidney function is involved, separate renal evidence from voiding symptoms. Use lab dates, eGFR/GFR, creatinine, albumin/creatinine ratio, nephrology notes, dialysis or transplant facts if applicable, and provider interpretation. If urinary residuals are predominant, keep renal records available without forcing them into the wrong lane.

9. ED, SMC-K, scars, and surgical residuals

Prostate cancer treatment can leave residual issues that need their own documentation. ED may support SMC-K when service connected and properly documented. Surgical scars need location, size, pain, instability, and functional impact facts. Do not assume VA will automatically infer these from a prostatectomy record.

10. Work and daily-function impact

Document practical limits: bathroom access needs, changing pads at work, avoiding long drives, sleep disruption from nighttime voiding, appointment burden, fatigue after treatment, hygiene burden, relationship impact, or missed shifts. Keep the language factual and specific.

What the DBQs should document

The public VA Male Reproductive Organ Conditions DBQ is the main planning map for prostate cancer and male reproductive residuals. It asks about diagnoses, medical history, treatment, voiding dysfunction, ED, retrograde ejaculation, infections, tumors or neoplasms, scars, diagnostic testing, and functional impact.

The public VA Urinary Tract Conditions DBQ can also matter when the residual picture centers on leakage, urinary frequency, obstruction, catheterization, infection, or other urinary facts. If the exam uses only one DBQ and leaves a major residual blank, that gap should be identified before the next filing or review step.

DBQ field	Why it matters	Before-exam prep
Tumor or neoplasm history	Shows active status, treatment status, and whether residual review is appropriate.	Bring treatment dates, oncology records, and recurrence or remission notes.
Voiding dysfunction	Maps the residual to leakage, frequency, appliance, catheter, or obstruction facts.	Prepare bladder and pad-change logs with dates and typical ranges.
ED and reproductive residuals	May support service-connected ED and SMC-K review.	Gather diagnosis, treatment, onset after cancer treatment, and functional facts.
Scars	Surgical scars can be a separate evidence lane when painful, unstable, large, or function-limiting.	Record scar location, size, pain, instability, numbness, and photos if appropriate.
Functional impact	Connects residuals to work, daily life, sleep, hygiene, driving, and reliability.	Write concrete examples before the exam so the impact is not understated.

Service-connection and exposure evidence

The rating evidence is only one half of the file. The service-connection path must also be clear. Some veterans already have prostate cancer service connected and are only disputing residual severity. Others are still building service connection through an exposure theory, direct service records, medical nexus evidence, or a presumptive path.

VA lists prostate cancer as an Agent Orange presumptive condition. That does not mean every veteran should self-file based on a single sentence. The record still needs the correct service location or exposure facts, diagnosis proof, and the right filing posture. If the case involves a denial, an effective-date dispute, or a proposed reduction, review the decision language carefully with an accredited representative or qualified adviser.

Common mistakes that weaken residual ratings

• Submitting cancer records but no residual proof: post-treatment ratings need current severity facts, not only old diagnosis records.
• Missing the treatment end date: the six-month review depends on when treatment stopped, so the timeline should be visible.
• Using vague urinary language: "I leak" is weaker than documented pad changes, appliance use, frequency intervals, and nighttime counts.
• Ignoring ED and SMC-K: ED can matter even when the schedular ED rating is 0% if the condition is service connected and SMC-K facts are present.
• Mixing renal and voiding evidence: kidney-function labs and urinary leakage are different evidence lanes.
• Assuming recurrence from PSA alone: lab trends should be interpreted by a clinician and supported by oncology records.
• Forgetting scars: prostate surgery scars should be documented if they are painful, unstable, large, numb, or limiting.

How to organize the file

Use a one-page index before uploading more records. Separate the file into diagnosis, treatment timeline, six-month review, recurrence status, voiding dysfunction, renal dysfunction, ED/SMC-K, scars, functional impact, and service-connection evidence. Label each PDF with a date and purpose.

A practical upload order might look like this:

1. Pathology or diagnosis record
2. Treatment timeline summary
3. Surgery, radiation, chemotherapy, hormone-treatment, or oncology records
4. Current PSA and recurrence-status evidence
5. Male Reproductive Organ DBQ or urology note
6. Urinary Tract DBQ, bladder log, pad-change log, catheter or appliance records
7. Kidney labs or nephrology records if renal dysfunction is involved
8. ED, SMC-K, scar, and functional-impact evidence
9. Decision letter or proposed reduction notice if this is a review issue

How TYFYS fits into the process

TYFYS helps veterans identify whether a prostate cancer residuals file has a treatment-timeline gap, six-month-review gap, residual-severity gap, DBQ gap, ED/SMC-K gap, scar gap, exposure-evidence gap, or decision-letter gap. We do not file claims, provide legal advice, or act as a VSO. We help organize private medical evidence so the claim story is clearer before the next filing, exam, or review step.

FAQ: VA prostate cancer residuals ratings

Does VA rate active prostate cancer at 100%?

VA's genitourinary schedule lists malignant neoplasms of the genitourinary system at 100% under Diagnostic Code 7528. After treatment ends, the schedule calls for a mandatory VA examination at six months and then residual rating if there is no local recurrence or metastasis.

What evidence matters after prostate cancer treatment ends?

Key evidence includes treatment end dates, oncology follow-ups, recurrence or metastasis status, PSA trend interpretation, voiding dysfunction details, pad changes, urinary frequency, catheter or appliance use, renal dysfunction labs, ED/SMC-K facts, scars, and functional impact.

Can prostate cancer residuals be rated for urinary leakage?

Yes, when leakage is the predominant residual and the evidence supports it. The file should document absorbent material use, how often materials are changed per day, appliance use if applicable, and medical records tying the leakage to the prostate cancer residuals.

Can ED after prostate cancer treatment support SMC-K?

Potentially, if ED is service connected and the evidence establishes the qualifying loss-of-use facts. The ED rating itself may be 0%, so veterans should check whether SMC-K was granted, denied, or not addressed in the decision.

What should a bladder log include?

A bladder log should include dates, daytime voiding times, nighttime wake-ups to void, leakage episodes, pad changes, catheter or appliance use if applicable, fluid timing, and work or sleep impact. Pair the log with medical records whenever possible.

Is prostate cancer presumptive for Agent Orange exposure?

VA lists prostate cancer as an Agent Orange presumptive condition. The file still needs the correct exposure or service-location facts, diagnosis proof, and the right claim posture. Legal and effective-date questions should be reviewed with an accredited representative or qualified adviser.